NO20004251L - Humanized anti-CEA high affinity monoclonal antibodies - Google Patents

Humanized anti-CEA high affinity monoclonal antibodies

Info

Publication number
NO20004251L
NO20004251L NO20004251A NO20004251A NO20004251L NO 20004251 L NO20004251 L NO 20004251L NO 20004251 A NO20004251 A NO 20004251A NO 20004251 A NO20004251 A NO 20004251A NO 20004251 L NO20004251 L NO 20004251L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
high affinity
humanized anti
affinity monoclonal
tag
Prior art date
Application number
NO20004251A
Other languages
Norwegian (no)
Other versions
NO20004251D0 (en
Inventor
William Henry Kerr Anderson
Philip R Tempest
Frank J Carr
William J Harris
Kathryn Armour
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of NO20004251D0 publication Critical patent/NO20004251D0/en
Publication of NO20004251L publication Critical patent/NO20004251L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nye humaniserte monoklonale antistoffer, humaniserte antistoff-fragmenter og derivater derav som spesifikt binder TAG-72 er beskrevet, samt fremgangsmåter for fremstilling derav. Disse humaniserte antistoffene er nyttige for behandling av cancer som uttrykker TAG-72 samt for diagnostiske formål, f.eks iv vivo billed-dannelse av tumorer eller cancerceller som uttrykker TAG-72.New humanized monoclonal antibodies, humanized antibody fragments and derivatives thereof that specifically bind TAG-72 are described, as well as methods for their production. These humanized antibodies are useful for the treatment of cancers that express TAG-72 as well as for diagnostic purposes, eg iv vivo imaging of tumors or cancer cells that express TAG-72.

NO20004251A 1998-02-25 2000-08-24 Humanized anti-CEA high affinity monoclonal antibodies NO20004251L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003680 WO1999043817A1 (en) 1998-02-25 1998-02-25 High affinity humanized anti-cea monoclonal antibodies

Publications (2)

Publication Number Publication Date
NO20004251D0 NO20004251D0 (en) 2000-08-24
NO20004251L true NO20004251L (en) 2000-10-24

Family

ID=22266464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004251A NO20004251L (en) 1998-02-25 2000-08-24 Humanized anti-CEA high affinity monoclonal antibodies

Country Status (7)

Country Link
EP (1) EP1056859A1 (en)
JP (1) JP2002504372A (en)
AU (1) AU752494B2 (en)
CA (1) CA2321947A1 (en)
IL (1) IL138022A0 (en)
NO (1) NO20004251L (en)
WO (1) WO1999043817A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502727A (en) * 2001-09-21 2005-01-27 カプリオン ファーマシューティカルズ インコーポレーティッド Method for preparing highly purified plasma membrane
SG162726A1 (en) * 2005-05-27 2010-07-29 San Raffaele Centro Fond Gene vector comprising mi-rna
BR112013021460B1 (en) * 2011-03-02 2022-12-20 Roche Glycart Ag ANTIBODIES, COMPOSITION AND USE OF THE ANTIBODY
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
CN106749667B (en) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 A nanobody against carcinoembryonic antigen and its application
JP2022539344A (en) 2019-06-26 2022-09-08 江蘇恒瑞医薬股▲ふん▼有限公司 Anti-CEA antibody and its application
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
IL138022A0 (en) 2001-10-31
AU752494B2 (en) 2002-09-19
WO1999043817A1 (en) 1999-09-02
CA2321947A1 (en) 1999-09-02
JP2002504372A (en) 2002-02-12
EP1056859A1 (en) 2000-12-06
AU6338898A (en) 1999-09-15
NO20004251D0 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
WO1999004265A3 (en) Cancer associated nucleic acids and polypeptides
NO175944C (en) Monoclonal antibodies for use in in vitro detection of tumor-associated mucin antigen, and hybridoma cell lines producing these
DE69734109D1 (en) Humanization of anti-carcinoembryonic antigen anti-idiotypic antibodies and their use as a tumor vaccine and for labeling
ATE524196T1 (en) ANTIBODIES BINDING TO THE CANCER-ASSOCIATED ANTIGEN CD46 AND METHOD OF USE THEREOF
CY1113326T1 (en) HUMAN ANTIBODIES THAT CONNECT HUMAN IL-12 AND ITS PRODUCTION METHODS
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
TR200102507T2 (en) Compositions for the treatment of ovarian cancer.
MX9701859A (en) Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor.
MX9504802A (en) Anti-egfr single-chain fvs and anti-egfr antibodies.
HUP9901562A2 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
DK1565489T3 (en) Internalizing antibodies specific for the RAAG10 cell surface target
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
AU2829889A (en) Sf-25 colon adenocarcinoma antigen, and antibodies which recognize this antigen
WO2003064593A3 (en) Antigen panels and methods of using the same
NO20004251L (en) Humanized anti-CEA high affinity monoclonal antibodies
NO20004250D0 (en) Humanized anti-TAG-72 high affinity monoclonal antibodies
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
EA200601405A1 (en) HUMANIZED ANTIBODY
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2003024302A3 (en) Detection and treatment of cancers of breast
WO2003024304A3 (en) Detection and treatment of cancers of the liver

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application